Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Eli Lilly and Co. (NYSE: LLY) shares are experiencing increased activity Friday afternoon. Here's what you need to know.
A study finds that GLP-1 treatments, including Novo Nordisk's Ozempic and Eli Lilly's Mounjaro, significantly reduce th...
https://news.bloomberglaw.com/health-law-and-business/ozempic-may-lower-risk-of-obesity-related-cancers-study-finds
Morgan Stanley analyst Terence Flynn maintains Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $1023 price target.
The S&P 500 and Nasdaq 100 indices surged to new all-time highs on Thursday, as investors heightened their expectations for...
The FDA has approved Eli Lilly's Kisunla (donanemab) for early symptomatic Alzheimer's disease. Kisunla, targeting amyl...
https://www.statnews.com/2024/07/03/ozempic-wegovy-naion-vision-loss-study/A new observational study on Wednesday reported for ...
